JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Editas Medicine Inc

Fermé

SecteurSoins de santé

3.14 -3.68

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.13

Max

3.19

Chiffres clés

By Trading Economics

Revenu

-31M

-76M

Ventes

-26M

4.7M

Marge bénéficiaire

-1,633.491

Employés

246

EBITDA

-28M

-72M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+0.32% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

135M

264M

Ouverture précédente

6.82

Clôture précédente

3.14

Sentiment de l'Actualité

By Acuity

50%

50%

145 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 juil. 2025, 17:53 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 juil. 2025, 15:58 UTC

Résultats
Principaux Mouvements du Marché

Aon Shares Rise After 2Q Earnings Beat

25 juil. 2025, 15:08 UTC

Principaux Mouvements du Marché

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 juil. 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 juil. 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 juil. 2025, 20:40 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 20:10 UTC

Résultats

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 19:56 UTC

Résultats

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 juil. 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 juil. 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 juil. 2025, 19:01 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 juil. 2025, 17:38 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 juil. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 juil. 2025, 17:13 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 16:46 UTC

Résultats

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 juil. 2025, 16:45 UTC

Résultats

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 juil. 2025, 16:27 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 juil. 2025, 16:02 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 juil. 2025, 15:34 UTC

Résultats

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 juil. 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 juil. 2025, 15:05 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 juil. 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 juil. 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 juil. 2025, 14:36 UTC

Market Talk
Résultats

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

0.32% hausse

Prévisions sur 12 Mois

Moyen 3.16 USD  0.32%

Haut 4 USD

Bas 1 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

4

Achat

5

Maintien

1

Vente

Score Technique

By Trading Central

1.33 / 1.54Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

No Evidence

Sentiment

By Acuity

145 / 375Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.